Skip to main content
Clinical Trials/NCT01470157
NCT01470157
Unknown
Phase 4

A Randomized, Clinical Trial of Oral Midazolam Plus Placebo Versus Oral Midazolam Plus Oral Ketamine for Sedation During Laceration Repair

Assaf-Harofeh Medical Center1 site in 1 country60 target enrollmentJuly 2011

Overview

Phase
Phase 4
Intervention
Ketamine
Conditions
Lacertaions
Sponsor
Assaf-Harofeh Medical Center
Enrollment
60
Locations
1
Primary Endpoint
Pain score: Visual analog score (VAS)- by parent
Last Updated
14 years ago

Overview

Brief Summary

Background: Sedation is often needed for young children undergoing minor procedures in the emergency department (ED). Oral midazolam is one of the most commonly used regimens for children undergoing laceration repair but its sedative efficacy was shown to be suboptimal. In a few studies oral ketamine has been used successfully for procedural sedation as well. The efficacy of using a combination of oral midazolam and oral ketamine for procedural sedation has been studied only for invasive procedures in children with malignancies. No randomized controedll studies were performed using this sedative combination in children requiring laceration repair. Objectives: To determine the efficacy of adding oral ketamine to oral midazolam for procedural sedation in children requiring laceration repair compares to oral midazolam plus placebo. Design: A randomized, double blind, placebo-controlled study. Setting: Pediatric Emergency Department. Participants: Children 1 to 10 years with laceration requiring sedation. Interventions: Eligible patients will be randomly assigned to one of two treatment groups: oral midazolam plus oral placebo group and oral midazolam plus oral ketamine group. Both groups will be given the same volume of medications. Midazolam will be given orally in a dose of 0.5 mg/kg (max.-15 mg) with placebo or 0.5 mg/kg (max.- 15 mg) with oral ketamine in a dose of 5 mg/kg. The medical staff will be blinded to the treatment given. Patient monitoring will be conducted according to the American Academy of Pediatrics (APP) and the Israeli health ministry guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Main outcome measures: Pain score: Visual Analog Score (VAS) - by parent. Data analysis: Descriptive statistics will be used to describe the study population. Data will be analyzed using t- tests for continuous data and Fisher exact test for categorical data.

Key words: sedation, children, ketamine, midazolam, emergency department.

Registry
clinicaltrials.gov
Start Date
July 2011
End Date
July 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Assaf Harofeh MC

Director, Pediatric Emergency Unit

Assaf-Harofeh Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age: 1 years - 10 years
  • Any child with laceration requiring sedation

Exclusion Criteria

  • Major trauma
  • Closed head injury associated with loss of consciousness
  • Abnormal neurologic examination in a previously normal child
  • Significant developmental delay or baseline neurological deficit
  • A patient with seizures
  • Elevated intra-cranial pressure
  • Hypersensitivity to midazolam or ketamine
  • Hypertension
  • Hyperthyroidism or a patient receiving thyroid replacement
  • alcohol intoxication or a history of alcohol abuse

Arms & Interventions

Ketamine

Oral Ketamine in addition to oral midazolam

Intervention: Ketamine

Placebo

Normal saline (placebo) in addition to oral midazolam

Intervention: Normal Saline

Outcomes

Primary Outcomes

Pain score: Visual analog score (VAS)- by parent

Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 hours

Secondary Outcomes

  • Pain score: Visual analog score (VAS)- by a physician(while in the ED for about 3 hours)

Study Sites (1)

Loading locations...

Similar Trials